Membranoproliferative GN I
Alternative names:
glomerulonephritis - membranoproliferative (type 1); lobular GN; membranoproliferative glomerulonephritis type 1; mesangiocapillary glomerulonephritis (type 1); MPGN1
Treatment:
Treatment may vary according to the symptoms. Treatment goals include reduction of symptoms, prevention of complications, and slowed progression of the disorder.
Dietary adjustments may include restrictions on sodium (see sodium in diet), fluids, protein, or other restrictions as appropriate to control high blood pressure, swelling, and accumulation of waste products in the bloodstream.
Antihypertensive medications are critical to help control blood pressure. Diuretics or other medications may be appropriate to control edema or other symptoms.
Dialysis or kidney transplant may eventually be required to manage renal failure. Combination therapy with aspirin and dipyridamole may slow progression to renal failure with MPGN 1. This treatment is of unproven value.
Expectations (prognosis):
The disorder progresses slowly to chronic renal failure. Fifty percent of cases will develop chronic renal failure within 10 years.
Complications:
Calling your health care provider:
Call for an appointment with your health care provider if symptoms indicate MPGN I may be present.
Call for an appointment with your health care provider if symptoms worsen or persist, or if new symptoms develop, including decreased urine output.
|
